the evidence atlas · 36 compounds graded A to F · 13 body systems
fat & metabolism: what peptide research shows
12 graded compounds were studied for fat & metabolism. Each is graded A to F on published evidence; the ladder shows how far research got, from cell studies to approval.
selected systemclick a glowing region to explore itclick a region · drag to rotate
- Liraglutidemeasured in people$10.20/mg
- Semaglutidemeasured in people$6.00/mg
- Tesamorelinmeasured in people$7.50/mg
- Tirzepatidemeasured in people$3.50/mg
- Cagrilintidemeasured in people$10.00/mg
- Mazdutidemeasured in people
- Retatrutidemeasured in people$6.25/mg
- Survodutidemeasured in people
- 5-Amino-1MQanimal or cell studies$1.20/mg
- MOTS-canimal or cell studies$3.50/mg
- SLU-PP-332animal or cell studies$15.00/mg
- AOD-9604measured in people$5.00/mg
research market · not for human use
A lit region shows where studies measured an effect, not that a compound works there. Most research-market compounds are not FDA-approved.
Evidence grades come from the published literature; no vendor can pay for a grade or a ranking. Some outbound links are affiliate links; they never affect grades, scores or order.
fat & metabolism
evidence table
| compound | grade | highest rung | US status | body systems | from $/mg |
|---|---|---|---|---|---|
| Liraglutide GLP-1 agonist | approved somewhere | FDA-approved | fat & metabolism, gut, heart | $10.20 | |
| Semaglutide GLP-1 agonist | approved somewhere | FDA-approved | fat & metabolism, gut, heart, kidneys, liver | $6.00 | |
| Tesamorelin GHRH analogue | approved somewhere | FDA-approved | hormone axis, fat & metabolism, liver | $7.50 | |
| Tirzepatide GIP/GLP-1 dual agonist | approved somewhere | FDA-approved | fat & metabolism, gut, liver, heart, lungs & airway | $3.50 | |
| Cagrilintide long-acting amylin analogue | phase 3 trial | investigational | fat & metabolism, gut, brain & mood | $10.00 | |
| Mazdutide glucagon/GLP-1 dual agonist | phase 3 trial | investigational | fat & metabolism, liver | — | |
| Retatrutide GIP/GLP-1/glucagon triple agonist | phase 2 trial | investigational | fat & metabolism, liver, gut | $6.25 | |
| Survodutide glucagon/GLP-1 dual agonist | phase 2 trial | investigational | fat & metabolism, liver | — | |
| 5-Amino-1MQ NNMT inhibitor | animal studies | research only | fat & metabolism, muscle | $1.20 | |
| MOTS-c mitochondrial-derived peptide | animal studies | rulemaking pending | muscle, fat & metabolism | $3.50 | |
| SLU-PP-332 ERR agonist | animal studies | research only | muscle, fat & metabolism | $15.00 | |
| AOD-9604 hGH fragment 177–191 | phase 2 trial | compounding restricted | fat & metabolism | $5.00 |
short answers
atlas questions
What is the evidence atlas?
A map of where peptides have been studied in the body and how strong that research is. Each compound has one grade from A (approved, strong human outcome data) to F (contradicted, unsafe, or identity problems), plus the highest rung of evidence it reached.
What is the evidence ladder?
Six rungs: cell studies, animal studies, small human studies, a phase 2 trial, a phase 3 trial, approval somewhere in the world. The ladder shows how far research got; the grade says what it found. AOD-9604 reached phase 2b and still grades F because the trial failed.
What does a glowing region mean?
That published studies measured an effect there. Mint means it was measured in people; periwinkle means animals or cells only. A lit region is not a claim that a compound works there.
Can a vendor pay for a better grade or ranking?
No. Evidence grades come from the published literature and vendor grades from lab data. Some outbound links are affiliate links; they never affect grades, scores or order.
Is this medical advice?
No. PeptideTech is an independent information service. Research-market compounds are sold as research chemicals and most are not approved for use in people.